Switch theme
Sign up to access all valuation multiples
Revvity provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments. First, its diagnostics segment includes immunodiagnostics, reproductive health, and applied genomics. Second, its discovery and analytical solutions is composed of life science, industrial, environmental, and food applications. Revvity offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software.
1947
11K+
LTM Revenue $2.8B
LTM EBITDA $861M
$12.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Revvity has a last 12-month revenue (LTM) of $2.8B and a last 12-month EBITDA of $861M.
In the most recent fiscal year, Revvity achieved revenue of $2.8B and an EBITDA of $840M.
Revvity expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Revvity valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.8B | XXX | $2.8B | XXX | XXX | XXX |
| Gross Profit | $1.7B | XXX | $1.5B | XXX | XXX | XXX |
| Gross Margin | 61% | XXX | 56% | XXX | XXX | XXX |
| EBITDA | $861M | XXX | $840M | XXX | XXX | XXX |
| EBITDA Margin | 31% | XXX | 30% | XXX | XXX | XXX |
| EBIT | $787M | XXX | $347M | XXX | XXX | XXX |
| EBIT Margin | 28% | XXX | 13% | XXX | XXX | XXX |
| Net Profit | $595M | XXX | $270M | XXX | XXX | XXX |
| Net Margin | 21% | XXX | 10% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $2.0B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Revvity's stock price is $90.
Revvity has current market cap of $10.7B, and EV of $12.8B.
See Revvity trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $12.8B | $10.7B | XXX | XXX | XXX | XXX | $4.91 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Revvity has market cap of $10.7B and EV of $12.8B.
Revvity's trades at 4.7x EV/Revenue multiple, and 15.3x EV/EBITDA.
Equity research analysts estimate Revvity's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Revvity has a P/E ratio of 17.9x.
See valuation multiples for Revvity and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $10.7B | XXX | $10.7B | XXX | XXX | XXX |
| EV (current) | $12.8B | XXX | $12.8B | XXX | XXX | XXX |
| EV/Revenue | 4.6x | XXX | 4.7x | XXX | XXX | XXX |
| EV/EBITDA | 14.9x | XXX | 15.3x | XXX | XXX | XXX |
| EV/EBIT | 16.3x | XXX | 37.0x | XXX | XXX | XXX |
| EV/Gross Profit | 7.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | 17.9x | XXX | 39.4x | XXX | XXX | XXX |
| EV/FCF | 23.7x | XXX | 23.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialRevvity's last 12 month revenue growth is 4%
Revvity's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Revvity's rule of 40 is 30% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Revvity's rule of X is 42% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Revvity and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 4% | XXX | 5% | XXX | XXX | XXX |
| EBITDA Margin | 31% | XXX | 30% | XXX | XXX | XXX |
| EBITDA Growth | 5% | XXX | 11% | XXX | XXX | XXX |
| Rule of 40 | 30% | XXX | 35% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 42% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 7% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 43% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| Integral Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
| Sonic Healthcare | XXX | XXX | XXX | XXX | XXX | XXX |
| Bangkok Dusit Medical Services | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Revvity acquired XXX companies to date.
Last acquisition by Revvity was XXXXXXXX, XXXXX XXXXX XXXXXX . Revvity acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Revvity founded? | Revvity was founded in 1947. |
| Where is Revvity headquartered? | Revvity is headquartered in United States of America. |
| How many employees does Revvity have? | As of today, Revvity has 11K+ employees. |
| Who is the CEO of Revvity? | Revvity's CEO is Dr. Prahlad R. Singh, PhD. |
| Is Revvity publicy listed? | Yes, Revvity is a public company listed on NYS. |
| What is the stock symbol of Revvity? | Revvity trades under RVTY ticker. |
| When did Revvity go public? | Revvity went public in 1983. |
| Who are competitors of Revvity? | Similar companies to Revvity include e.g. Australian Clinical Labs, Healius, Integral Diagnostics, Sonic Healthcare. |
| What is the current market cap of Revvity? | Revvity's current market cap is $10.7B |
| What is the current revenue of Revvity? | Revvity's last 12 months revenue is $2.8B. |
| What is the current revenue growth of Revvity? | Revvity revenue growth (NTM/LTM) is 4%. |
| What is the current EV/Revenue multiple of Revvity? | Current revenue multiple of Revvity is 4.6x. |
| Is Revvity profitable? | Yes, Revvity is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Revvity? | Revvity's last 12 months EBITDA is $861M. |
| What is Revvity's EBITDA margin? | Revvity's last 12 months EBITDA margin is 31%. |
| What is the current EV/EBITDA multiple of Revvity? | Current EBITDA multiple of Revvity is 14.9x. |
| What is the current FCF of Revvity? | Revvity's last 12 months FCF is $543M. |
| What is Revvity's FCF margin? | Revvity's last 12 months FCF margin is 19%. |
| What is the current EV/FCF multiple of Revvity? | Current FCF multiple of Revvity is 23.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
